# Pluvicto (lutetium lu-177 vipivotide tetraxetan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan

> The FDA approved Pluvicto (lutetium lu-177 vipivotide tetraxetan), sponsored by NOVARTIS AG (NVS), on March 23, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Pluvicto (lutetium lu-177 vipivotide tetraxetan) FDA approved?

Yes. The FDA approved Pluvicto (lutetium lu-177 vipivotide tetraxetan), sponsored by NOVARTIS AG (NVS), on March 23, 2022. FDA novel drug approvals: "Pluvicto | lutetium (177Lu) vipivotide tetraxetan | 3/23/2022 | To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapiesDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Pluvicto (lutetium lu-177 vipivotide tetraxetan) |
| Codes |  |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### March 23, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Pluvicto | lutetium (177Lu) vipivotide tetraxetan | 3/23/2022 | To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapiesDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA215833 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20220323, review_priority PRIORITY; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22

### March 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215833 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22

### July 31, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215833 SUPPL-37 (Efficacy): submission_status AP, submission_status_date 20260731, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pluvicto (lutetium lu-177 vipivotide tetraxetan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan

```bibtex
@misc{secapidev_pdufa_lutetium_lu_177_vipivotide_tetraxetan_20261116,
  title        = {Pluvicto (lutetium lu-177 vipivotide tetraxetan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_lutetium_lu_177_vipivotide_tetraxetan_20261116","title":"Pluvicto (lutetium lu-177 vipivotide tetraxetan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
